ArticleCellular & molecular biology letters2025
CD209a regulates metabolic dysfunction-associated steatotic liver disease development through macrophage STAT3 signaling pathway.
Article in Cellular & molecular biology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Review
- Dysregulation of the AMPK-SREBP1-FASN axis in MASLD: driving a vicious cycle of lipotoxicity and metabolic-immune crosstalk.Lipids in health and disease · 2026Review
- Macrophage duality in liver diseases: heterogeneity, plasticity, and the quest for precision therapeutics.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is a growing global health concern, with macrophage-driven inflammation playing a critical role in its progression. CD209a, a C-type lectin receptor, has been implicated in immune regulation, but its function in MASLD remains unclear. This study investigates the role of CD209a in MASLD pathogenesis, focusing on its effects on macrophage-mediated inflammation.
methodsWe analyzed CD209a expression in liver tissues from patients with MASLD and diet-induced MASLD mouse models. CD209a knockout (Cd209a−/−) mice were generated, and bone marrow transplantation was conducted to assess the impact of CD209a deficiency on hepatic steatosis, inflammation, and insulin resistance. Macrophage depletion was performed to determine whether the impact is mediated by liver macrophages. Single-cell RNA sequencing (scRNA-seq) was utilized to explore macrophage phenotypic changes and underlying signaling pathways.
resultsCD209a expression was significantly upregulated in livers of patients and mice with MASLD. Cd209a−/− mice exhibited aggravated hepatic steatosis, inflammation, and insulin resistance compared with wild-type controls (P < 0.05). Macrophage depletion abolished these effects, confirming a macrophage-dependent mechanism. Single-cell RNA-seq revealed that CD209a deficiency caused a shift toward a proinflammatory macrophage phenotype, with STAT3 signaling identified as a potential mediator.
conclusionsCD209a plays a protective role in MASLD. Loss of CD209a promotes macrophage-driven inflammation through STAT3 signaling and exacerbates MASLD severity. CD209a may serve as a potential therapeutic target for MASLD management, warranting further translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.